Cargando…

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©

Background: OncotypeDX Recurrence Score© (RS) is a commercially available 21-gene expression assay which estimates prognosis and guides chemoendocrine prescription in early-stage estrogen-receptor positive, human epidermal growth factor receptor-2-negative (ER+/HER2−) breast cancer. Limitations of R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davey, Matthew G., Jalali, Amirhossein, Ryan, Éanna J., McLaughlin, Ray P., Sweeney, Karl J., Barry, Michael K., Malone, Carmel M., Keane, Maccon M., Lowery, Aoife J., Miller, Nicola, Kerin, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318604/ https://www.ncbi.nlm.nih.gov/pubmed/35887614 http://dx.doi.org/10.3390/jpm12071117

Ejemplares similares

Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer
por: Kerin, Eoin P., et al.
Publicado: (2022)

Is radiomic MRI a feasible alternative to OncotypeDX(®) recurrence score testing? A systematic review and meta-analysis
por: Davey, M G, et al.
Publicado: (2021)

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
por: Malo, Teri L., et al.
Publicado: (2012)

The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre
por: McVeigh, Terri Patricia, et al.
Publicado: (2014)

Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay
por: Jacobs, Michael A., et al.
Publicado: (2020)

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
por: Goldstein, Daniel A., et al.
Publicado: (2020)

Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria
por: Jahn, B., et al.
Publicado: (2015)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
por: Feldman, Didi, et al.
Publicado: (2023)

Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017)

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
por: McVeigh, Terri P, et al.
Publicado: (2017)

A Radio-genomics Approach for Identifying High Risk Estrogen Receptor-positive Breast Cancers on DCE-MRI: Preliminary Results in Predicting OncotypeDX Risk Scores
por: Wan, Tao, et al.
Publicado: (2016)

Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study
por: Davey, Matthew G., et al.
Publicado: (2021)

Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
por: Jahn, Beate, et al.
Publicado: (2017)

Oncotype Dx Results in Multiple Primary Breast Cancers
por: Toole, Michael J., et al.
Publicado: (2014)

Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score
por: Zhang, Michelle, et al.
Publicado: (2021)

Spotlight on the utility of the Oncotype DX(®) breast cancer assay
por: Siow, Zhen Rong, et al.
Publicado: (2018)

Oncotype DX: Where Does It Stand in India?
por: Batra, Atul, et al.
Publicado: (2019)

Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022)

Breast cancer recurrence: factors impacting occurrence and survival
por: Courtney, Donald, et al.
Publicado: (2022)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

Use of Oncotype DX in Women with Node-Positive Breast Cancer
por: Ishibe, Naoko, et al.
Publicado: (2011)

Utilization of Oncotype DX in an Inner City Population: Race or Place?
por: Guth, Amber A., et al.
Publicado: (2013)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
por: Hanna, Matthew G., et al.
Publicado: (2017)

Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis
por: Davey, Matthew G., et al.
Publicado: (2022)

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
por: Aherne, T. M., et al.
Publicado: (2020)

The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting
por: Choi, Joseph Do Woong, et al.
Publicado: (2022)

Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
por: Kim, Jinkyoung, et al.
Publicado: (2019)

MiRNA expression deregulation correlates with the Oncotype DX(®) DCIS score
por: Loudig, Olivier, et al.
Publicado: (2022)

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
por: Collin, Lindsay J., et al.
Publicado: (2019)

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
por: Sahebjam, S, et al.
Publicado: (2011)

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017)

Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
por: Lalani, Nafisha, et al.
Publicado: (2017)

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
por: Sengupta, Aditya K., et al.
Publicado: (2020)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
por: Zhu, Xiaofu, et al.
Publicado: (2021)

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
por: Iles, Kathleen, et al.
Publicado: (2022)

Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab
por: McGuire, Andrew, et al.
Publicado: (2017)

Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer
por: Mislick, Kimberly, et al.
Publicado: (2014)

Population-based study of hormone receptor status comparing Oncotype DX with standard immunohistochemistry
por: Baehner, FL, et al.
Publicado: (2009)

Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer
por: Whitney, Jon, et al.
Publicado: (2018)

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
por: Klein, Molly E, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_alhf6v3u151or81q905vq7lheo